The trial for the vaccine candidate, known as NVX-Covey 2373, will evaluate safety, efficacy, and immune response to 30,000 people aged 18 and over. It builds on phase 1/2 studies showing that the vaccine responds immunely and appears to be safe. The trial is investigating whether the vaccine prevents Covid-19 …
Read More »Novavax – CNN
